Timing clarification: McKesson is scheduled to report today, Wednesday, August 5, 2026, after the market closes—not tomorrow. The earnings call begins at 4:30 p.m. Eastern Time. (mckesson.com)
| Metric | Current expectation / outlook | Comparison |
|---|---|---|
| Adjusted EPS consensus | ~$9.56 | $8.26 last year; approximately 16% growth |
| Revenue consensus | ~$103.9 billion | $97.8 billion last year; approximately 6% growth |
| FY2027 adjusted EPS guidance | $43.80–$44.60 | 12%–14% reported growth |
| FY2027 revenue outlook | 5%–9% growth | |
| FY2027 adjusted operating-profit outlook | 8%–12% growth | |
| FY2027 free-cash-flow outlook | $4.5–$4.9 billion | $5.4 billion in FY2026 |
| Planned FY2027 repurchases | Approximately $5 billion |
Public consensus aggregators put fiscal Q1 adjusted EPS near $9.56 and revenue near $103.9 billion. Management’s full-year outlook assumes 116–118 million average diluted shares, a 17%–19% tax rate, $380–$420 million of interest expense and $295–$325 million of income attributable to noncontrolling interests. (marketbeat.com)
At the August 4 close of roughly $830, MCK trades at approximately 18.8 times the midpoint of FY2027 adjusted EPS guidance. That is not an extreme valuation for its earnings record, but it creates a higher bar than the headline consensus alone suggests: investors will probably want a clean operating beat and confidence in an eventual guidance increase.
The quarter is less about whether McKesson can generate another enormous revenue number and more about whether its higher-margin growth platforms can offset pharmaceutical price deflation and rising below-the-line costs.
A revenue miss caused by lower branded-drug prices would not necessarily be concerning. In fiscal Q4, branded pricing declines reduced North American Pharmaceutical revenue growth by approximately three percentage points, while neither those declines nor weaker sequential GLP-1 revenue affected segment operating profit. The more important measures are therefore:
Management entered FY2027 expecting this segment to deliver:
Fiscal Q4 provided a useful template. Revenue increased only 3%, but adjusted operating profit rose 11% as specialty distribution and operating efficiency outweighed branded-drug price pressure. GLP-1 distribution revenue was $14 billion, up 22% year over year but down 4% sequentially; full-year GLP-1 revenue increased 27% to $53 billion. (s24.q4cdn.com)
Investors should focus on:
Best outcome: revenue is noisy, but operating profit grows near or above the upper end of the full-year range.
Warning sign: price deflation or GLP-1 volatility begins affecting profit rather than only reported revenue.
This is increasingly the segment that supports McKesson’s valuation. Management expects FY2027 revenue growth of 14.5%–18.5% and operating-profit growth of 13.5%–17.5%.
Fiscal Q4 revenue rose 35% and adjusted operating profit increased 53%. Acquisitions contributed approximately 13 percentage points to revenue growth, but organic operating profit still grew approximately 13%. Management has characterized that low-teens organic rate as representative of the underlying business. (s24.q4cdn.com)
The Q1 comparison requires care:
The report should help investors distinguish acquisition-related growth from:
A result around 13% organic operating-profit growth would support the long-term thesis. Material deceleration would be more consequential than a consolidated revenue miss.
McKesson expects only 2.5%–6.5% revenue growth from Prescription Technology Solutions in FY2027, but 11%–15% operating-profit growth. That spread reflects the segment’s mix: third-party logistics represents roughly 55% of revenue and can fluctuate with product and program launches, while technology-based access and affordability programs drive more attractive profit growth. (s24.q4cdn.com)
Questions for the call include:
A modest revenue miss would be tolerable if access-solutions demand and operating profit remain strong. A slowdown in operating profit would be more meaningful.
McKesson previously expected to issue as much as $2.25 billion of additional Medical-Surgical term loans during the second half of fiscal Q1, supplementing the initial $1 billion term-loan financing. Apollo also agreed to invest $1.25 billion for approximately 13% of the business, implying a roughly $13 billion enterprise value. Proceeds are intended principally for share repurchases. (s24.q4cdn.com)
Investors need updates on:
The key distinction is between economic progress and accounting dilution. The separation financing raises interest expense, while Apollo’s stake will increase noncontrolling-interest deductions. A good report will show that operating growth and share-count reduction comfortably offset those headwinds.
The midpoint of FY2027 guidance is $44.20. Excluding prior-year Norway earnings and a $51 million U.S. Oncology Network investment gain, management said the outlook represents 14%–16% underlying EPS growth. (s24.q4cdn.com)
A guidance increase would be encouraging, but investors should examine its source:
Higher-quality increase
Lower-quality increase
Maintaining guidance would not automatically be disappointing after one quarter, particularly given the moving pieces around Medical-Surgical financing. Still, a strong Q1 without at least a more constructive full-year tone could be viewed as conservative.
McKesson’s first-quarter cash flow is heavily affected by working-capital timing. Fiscal Q1 2026 free cash flow was negative $1.1 billion, before the company finished the year at positive $5.4 billion. Investors should not extrapolate one quarter’s cash consumption without examining receivables, inventory and vendor-payment timing. (mckesson.com)
The more relevant issue is whether management remains comfortable with the FY2027 free-cash-flow target of $4.5–$4.9 billion.
Kenny Cheung became CFO effective May 29, succeeding Britt Vitalone. This will be his first quarterly report in the role, making commentary around guidance philosophy, capital deployment and separation accounting particularly relevant. (mckesson.com)
McKesson enters the report with a strong operating record and a credible path to low-to-mid-teens EPS growth. The principal attractions remain specialty distribution, community oncology, biopharma access services and aggressive capital return.
The main risk is that the stock is now valued on the assumption that these businesses can continue producing double-digit profit growth despite drug-price deflation, policy changes and separation-related costs. A headline EPS beat should be achievable, but the stock’s reaction is likely to depend on whether management demonstrates: